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Introduction
Nowadays, the number of new fixed-dose combina-
tions (FDCs) is rising significantly.  FDC is a medicine 
that includes two or more  active pharmaceutical ingredi-
ents (APIs) combined in a single dosage form. Due to this, 
the FDCs have several advantages over monocomponent 
medicine, such as potentiating the therapeutic efficacy, re-
ducing the incidence of adverse effect of medicines, having 
pharmacokinetic advantage, better compliance by reducing 
the pill burden, reducing dose of individual medicines, de-
creasing development of resistance, ensuring cause treat-
ment. No less important they are cheaper than individual 
medicine because of reduced cost from packaging to dis-
tribution. Nowadays, monotherapy is an unsuccessful treat-
ment of many cases, particularly chronic diseases, such as 
hypertension, diabetes, immunodeficiency virus (HIV), tu-
berculosis as well as hypopotassemia [1, 2, 3].
Hypopotassemia is serum potassium level less than 3.6 
mEq per L (3.6 mmol per L). It is a common electrolyte dis-
order, which occurs in up to 21% of hospitalized patients 
and 2% to 3% of outpatients [4, 5]. Hypopotassemia occurs 
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Abstract
Background: Compatibility determination between active pharmaceutical ingredients (APIs) in fixed-dose combinations is an indispensable step in the 
elaboration. High-performance liquid chromatography provides information on possible interactions between APIs and their related interaction products. 
The purpose of the present study was to investigate the compatibility of potassium orotate in combination with spironolactone by a HPLC method. 
Material and methods: The detection was carried out using Liquid Chromatograph Agilent 1100 with UV-VIS detector and a RP-18 reversed column 
(250*4 mm, 5 μm), mobile phase of acetonitrile: phosphate buffer solution (pH=4.0) with the ratio 1:49 and 1:1, at flow rate 1 and 1.5 mL/min, injection 
volume 20 μL; potassium orotate and spironolactone substances were provided by Sigma Aldrich, USA.
Results: Due to the developed method both separation and simultaneous qualitative and quantitative determination of APIs in the mechanical mixture 
were carried out. Spironolactone: retention time 6.9 min, concentration 98.1% (±0.21); potassium orotate: retention time 3.06 min, concentration 91.67% 
(±0.15). There were just well-separated symmetrical peaks of APIs and no additional peak in the chromatograms.
Conclusions: There is compatibility between APIs. Further studies will be performed by other methods (DSC, FT-IF Spectrometry) to confirm the 
obtained result.
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in less than 1% of healthy individuals, but is present in up 
to 20% of hospitalized patients, 40% of patients taking diu-
retics, and 17% of patients with cardiovascular conditions 
[6, 7]. Furthermore, as many as 20% of hospitalized patients 
are found to have hypopotassemia but only in 4–5% this 
is clinically significant  [8]. The high prevalence of hypo-
potassemia among patients with COVID-19 suggests the 
presence of disordered renin-angiotensin system activity, 
which increases as a result of reduced counter activity of 
angiotensin-converting enzyme 2, which is bound by severe 
acute respiratory syndrome coronavirus 2 [9].
Potassium (K+) plays a key role in maintaining normal 
cell function [10, 11]. K+  is the main intracellular cation 
and almost all cells have the pump called ‘Na+-K+-ATPase’, 
which pumps sodium (Na+) out of the cell and K+  into 
the cell leading to a K+ gradient across the cell membrane 
(K+ in > K+ out), which is partially responsible for maintain-
ing the potential difference across membrane [4, 11]. Many 
cell functions rely on this potential difference, particularly 
in excitable tissues, such as nerve and muscle. Two percent 
of K+ exist in the extracellular fluid (ECF) at a concentration 
of only 4mEq/L [10, 12]. Potassium is the third essential ele-
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ment in the human body after calcium and phosphorus and 
is the most abundant cation in the intracellular compart-
ment, which facilitates nerve impulse conduction and the 
contraction of skeletal and smooth muscles, including the 
heart. It controls the formation and storage of glycogen and 
prevents the calcium loss through the urine. If there is a po-
tassium lack, the lungs cannot remove the carbon dioxide 
and the kidneys cannot concentrate urine, resulting in ex-
cessive urination [13].
Hypopotassemia is frequently asymptomatic finding 
identified only on routine electrolyte screening. Clinical 
symptoms and signs of hypopotassemia depend on the rate 
of onset and severity.   It can be associated with symptoms 
ranging from the confusion, disorientation, weakness and 
discomfort of muscles to the arrhythmias, muscle cramps 
(paralysis), respiratory failure and sudden death [8, 14]. Hy-
popotassemia may be iatrogenically caused by other medi-
cines, such as furosemide, insulin, gentamicin, theophylline 
and salbutamol. Appropriately 80% of patients who are re-
ceiving diuretics (thiazide, loop) become hypopotassemic, 
while many of patients with hypopotassemia could also 
have an associated systemic disease [12, 13, 15].  Therefore 
with the application of loop diuretics and digoxin, hypopo-
tassemia  has become a frequent and feared side effect of 
treatment.
The correction of hypopotassemia depends on its se-
verity: mild (plasma potassium 3.1-3.5mmol/L), moder-
ate (plasma potassium 2.5-3.1mmol/L) and severe (plasma 
potassium <2.5mmol/L).  Urgent treatment is warranted 
for patients with potassium levels less than 2.5mEq/L by 
intravenous potassium chloride at 10-20 mEq/hour apply-
ing ECG monitoring and continuously careful estimation 
of serum potassium levels [12]. Mild and moderate hypo-
potassemia may be corrected by using an oral potassium 
supplementation (potassium chloride, potassium orotate, 
potassium aspartate) [16]. The most important is to correct 
underlying causes, for example, thiazide and loop diuretics 
can be replaced with the potassium-sparing diuretics, such 
as  spironolactone that leads to minimize potassium loss 
[17]. It is well-known that hypopotassemia can be induced 
by hypomagnesemia, therefore combination of potassium 
and magnesium aspartate provides potassium and magne-
sium correction, which resolves the cause of the imbalance 
[14, 18].
To gain the maximum benefit from treatment, we need 
to  use fixed-dose combinations that improve the potas-
sium supplementation and ensure etiological treatment 
in hypopotassemia. Unfortunately, there is a deficiency of 
a combined local pharmaceutical product on the pharma-
ceutical market of the Republic of Moldova. Therefore, the 
pharmaceutical product, which consists of potassium oro-
tate, potassium and magnesium aspartate, spironolactone, 
is in the process of development at the Scientific Center of 
Medicine. Due to this complex composition this new phar-
maceutical product can be applied not only to eliminate 
the symptoms of hypopotassemia (weakness, cramps), but 
also to ensure the causal treatment. Resulting from the fact, 
that combination of potassium and magnesium aspartate 
provides potassium and magnesium correction, because 
hypomagnesemia is linked to potassium imbalance.  Hypo-
potassemia in individuals with high blood pressure, who re-
quire taking thiazide diuretics, may be improved by replace-
ment or combination of it with a potassium-sparing diuretic 
(spironolactone). Very often potassium is used as an orotic 
acid salt that is a non-steroidal anabolic agent, which helps 
to normalize the external electrolyte balance of potassium 
through the stimulation of metabolic processes. Thus, due 
to these active substances combined in the single  dosage 
form for oral administration, it can produce better effect in 
the treatment of hypopotassemia, than any of them taken 
separately. Therefore, it is now in the active process of devel-
opment at the Scientific Center of Medicine [18, 20]. 
Definitely, various regulatory authorities, such as the 
Food and Drug Administration (FDA) and International 
Conference on Harmonization (ICH) require the pre-for-
mulation studies on each new FDC. Pre-formulation testing 
is an important step in the development of new products or 
the reformulation of existing ones. It includes the chemical 
characterization of the medicine and analytical compatibil-
ity/stability tests. In the pharmaceutical industry, the active 
pharmaceutical ingredient is subjected to pre-formulation 
studies, which provide the necessary information for the 
development of a stable medicine formulation with ad-
equate bioavailability [21]. Thus, it is designed to find out 
if the APIs have the potential to interact with each other 
or between APIs and excipient pharmaceutical ingredients 
(EPIs) [22, 23].
 
Fig. 1.  Chemical structure of potassium orotate
Incompatibility is an undesirable chemical or physical 
reaction between the API and EPIs or between two or more 
APIs that could reduce their effectiveness or result in toxic-
ity, increasing of minor or serious unexpected side effects. 
Physical and chemical interactions between APIs can affect 
the chemical nature, the stability and bioavailability of med-
icine products and consequently, their therapeutic efficacy 
and safety [24, 25].
Evaluation of possible incompatibilities between the 
APIs is an important part of the preformulation phase du-
ring the development of a dosage form. Successful compa-
tibility studies require a good experimental design that 
furnishes the required information with the minimum of 
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experimental effort. Definitely, not all APIs interactions 
are so bad, but major of them are life-threatening, there-
fore it is so necessary to determine them at the beginning of 
the medicine development phase by applying sensible and 
modern methods. Despite the importance of compatibility 
test between APIs, there is no universal protocol for this 
study. It is a key step in determining the success of medicine 
development [26].
To investigate the compatibility of the components of a 
formulation, techniques, such as X-ray diffraction, Fourier-
transform infrared spectroscopy   (FT-IR spectroscopy), 
high-performance liquid chromatography (HPLC) and 
thermal analysis (especially differential scanning calor-
imetry – DSC) are used [27-30].   Although DSC is a fast 
and reliable technique and generally regarded as one of the 
methods of first choice in assessing pharmaceutical compat-
ibility study, the evaluation of the curves is often difficult 
[31]. Therefore, this study was based on HPLC method, be-
cause it is easier than DSC and carries out qualitative and 
quantitative determinations of APIs and their related inter-
action products. Therefore, this method compares favorably 
with that commonly employed DSC and the values obtained 
by HPLC are of special importance.
The principal purpose of this study was to investigate the 
possible compatibility between the potassium orotate and 
spironolactone in the mixture by comparing the HPLC-ob-
tained chromatograms. Consequently, this study serves to 
give information on a medicine’s interaction, using HPLC 
method by providing not only qualitative but also quan-
titative results for pure APIs and their related interaction 
products. Analyses of HPLC chromatograms obtained on 
pure APIs and combinations of them made it possible to de-
termine the compatibility between APIs by comparing the 
following values: the number, shape and size of peaks. Due 
to the chemical structure of potassium and magnesium as-
partate and specifically to the lack of chromatophore groups 
they couldn’t be investigated by HPLC. Thus, HPLC method 
was applied for spironolactone and potassium orotate.
Potassium orotate is chemical potassium 2.4-dioxo-1H-
pyrimidine-6-carboxylate (potassium Uracil-6-carboxylate) 
(fig. 1). Its molecular formula is C5H3KN2O4 and its molecu-
lar weight is 194.19 g/mol. Potassium orotate is a bioavail-
able form of potassium (orotic acid helps it (K+) pass easily 
through cell membranes), that supports the nervous system, 
kidneys, cardiovascular health, bone strength, and encour-
ages a positive response to stress and anxiety.  Definitely, 
orotic acid is an intermediate in the pyrimidine biosynthe-
sis, which is required for DNA and RNA synthesis.
Spironolactone is a synthetic 17-spironolactone corticos-
teroid with  potassium-sparing diuretic, antihypertensive, 
and antiandrogen activities (fig. 2). Spironolactone compet-
itively inhibits adrenocortical hormone aldosterone activity 
in the distal renal tubules (it actually works on aldosterone-
dependent sodium- potassium exchange channels). This in-
creases the excretion of water and sodium, while decreasing 
the excretion of potassium. The increased excretion of water 
leads to diuretic and also antihypertensive effects. Spironol-
actone has a fairly slow onset of action, taking several days 
to develop; similarly, the effect diminishes slowly. 
Material and methods
The laboratory analyses were performed in the Labora-
tory of Pharmaceutical Chemistry, Faculty of Pharmacy, 
University of Graz, within the doctoral research mobility 
CIII-RO-0010-14-1920 – ”Teaching and Learning Bioanal-
ysis” under the leadership of professor Martin Schmid.
Materials
The HPLC-grade potassium orotate, HPLC-grade spi-
ronolactone, HPLC-grade acetonitrile (ACN) and analyti-
cal-grade potassium phosphate monobasic were provided 
by Sigma Aldrich (USA). HPLC-grade water was obtained 
from Fisher Chemical (Belgium).
Instrumentation and chromatographic conditions
The chromatographic analyses were performed by Liq-
uid Chromatograph Agilent 1100 equipped  with autosam-
pler.  The study was made on a RP-18 reversed column 
(250mm long by 4 mm internal diameter, particle size 5μm) 
and by an isocratic elution method. 
There are 2 elution techniques of pumping mobile phase 
through a column: isocratic and gradient methods. In the 
isocratic method, the composition of the mobile phase re-
mains constant, whereas in the gradient method the compo-
sition changes during the separation process. The isocratic 
method is the simplest technique and should be the first 
choice when developing a separation. Therefore, isocratic 
method of compatibility determination was selected to de-
termine compatibility of these studied 2 APIs in the mix-
ture.
In order to select a proper mobile phase for the good 
separation and quantitative determination of potassium 
orotate and spironolactone simultaneously, the chromato-
graphic conditions were selected after testing different pa-
rameters, such as diluents, buffer, buffer concentration, or-
ganic solvent for mobile phase, mobile phase composition, 
flow rate and temperature. Mobile phase selection was based 
on peak parameters (symmetry, tailing), run time, therefore 
two mobile phases were prepared.
Preparation of mobile phase n1:  2.72 g of potassium 
dihydrogen phosphate were weighed by balance (RAD-
Fig. 2.  Chemical structure of spironolactone
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WAG) and transferred to 1000 mL volumetric flask and dis-
solved by HPLC-grade water then completed to the mark 
by HPLC-grade water. The solution was adjusted to pH 4.0 
with 2M orthophosphoric acid. HPLC-grade acetonitrile 
and obtained phosphate buffer solution 0.02M were mixed 
with (1:49) ratio. The mobile phase was degassed in an ul-
trasonic bath (GT SONIC Professional Ultrasonic Cleaner, 
China). 
Preparation of mobile phase n2:  6.8 g of potassium 
dihydrogen phosphate were weighed by balance (RAD-
WAG) and transferred to 1000 mL volumetric flask and dis-
solved by HPLC-grade water then completed to the mark 
by HPLC-grade water. The solution was adjusted to pH 4.0 
with 2M orthophosphoric acid. HPLC-grade acetonitrile 
and obtained phosphate buffer solution 0.05M were mixed 
with (1:1) ratio. The mobile phase was degassed in the ul-
trasonic bath (GT SONIC Professional Ultrasonic Cleaner, 
China).
The study was performed on mobile phase N1 and at 
flow rate 1 mL/min, injection volume 20 μL, temperature 
25°C. The detection was set at 254 nm for spironolactone 
and at 278 nm for potassium orotate using UV-visible ab-
sorption detector.  Total run time was less than 20 min for 
each injection.
Preparation of standard and test solutions, made on 
mobile phase n1 (M/Ph. n1), in which potassium orotate 
is predominantly determined:
A standard and test potassium orotate solutions were pre-
pared in a 10-mL volumetric flask by dissolving 15.00 mg of 
the substance to be examined and then diluting to volume 
with mobile phase. Then this obtained solution undergoes 
a sonication for 30 seconds and then it is completed to the 
mark by mobile phase. Dilute 1mL of this solution to 10.0mL 
with mobile phase. Place 1mL of the obtained solution in the 
10-mL volumetric flask and make up to mark with mobile 
phase (the final solution contains 15 µg/mL). The solutions 
were scanned and found to have maximum absorption wave-
length at 278 nm using mobile phase as blank.
A standard and test spironolactone solutions were pre-
pared in the 10-mL volumetric flask by dissolving 2.40 mg 
of spironolactone and then diluting to volume with mobile 
phase. Then this obtained solution undergoes the sonication 
for 30 seconds and then it is completed to the mark by mo-
bile phase. Place 1 mL of this solution in a 5-mL volumetric 
flask and made up to mark with mobile phase (the final so-
lution contains 48 µg/mL). The solutions were scanned and 
weren’t found to have maximum absorption wavelength at 
240 nm using mobile phase as blank.
Test mixture preparation on M/Ph. N1: 2.40 mg of 
spironolactone and 15.00 mg of potassium orotate were 
weighed and mixed together with the ratio according to the 
amount of each APIs from the new fixed-dose combination, 
which is currently in progress. Whereupon, it was trans-
ferred into the 10-mL volumetric flask and then diluted to 
volume with mobile phase. The mixture was sonicated for 
a minimum of 30 seconds with intermittent shaking. Then 
the solution was brought back to room temperature and di-
luted to the mark with mobile phase. Dilute 1mL of this so-
lution to 5 mL with mobile phase. Place 1mL of the obtained 
solution in the 10-mL volumetric flask and make up to mark 
with mobile phase.
As well as the study was performed on mobile phase N2 
and at flow rate 1.5 mL/min, injection volume 20 μL, tem-
perature 40°C. The detection was set at 254 nm for spironol-
actone and at 278 nm for potassium orotate using UV-visi-
ble absorption detector.  Total run time was less than 10 min 
for each injection.
Preparation of standard and test solutions, made on 
mobile phase n2 (M/Ph. n2), in which spironolactone is 
predominantly determined:
A standard and test spironolactone solutions were pre-
pared in the 10-mL volumetric flask by dissolving 2.40 mg 
of the substance to be examined and then diluted to volume 
with mobile phase. Then this obtained solution undergoes 
the sonication for 30 seconds and then it is completed to the 
mark by mobile phase. Dilute 1mL of this solution in the 5.0 
mL with mobile phase. Place 1mL of the obtained solution 
in the 10-mL volumetric flask and make up to mark with 
mobile phase (the final solution contains 4.8µg/mL). The 
solutions were scanned and found to have maximum ab-
sorption wavelength at 240 nm using mobile phase as blank.
A standard and test potassium orotate solutions were pre-
pared in a 10-mL volumetric flask by dissolving 15.00 mg of 
the substance to be examined and then diluting to volume 
with mobile phase. Then this obtained solution undergoes 
the sonication for 30 seconds and then it is completed to the 
mark by mobile phase. Dilute 1mL of this solution to the 5.0 
mL with mobile phase. Place 1mL of the obtained solution 
in the 10-mL volumetric flask and make up to mark with 
mobile phase (the final solution contains 30µg/mL). The so-
lutions were scanned and found to have maximum absorp-
tion wavelength at 278 nm using mobile phase as blank.
Test mixture preparation on M/Ph. N2: 2.40 mg of 
spironolactone and 15.0 mg of potassium orotate were 
weighed and mixed together with the ratio according to the 
amount of each API from the new fixed-dose combination. 
Whereupon, it was transferred into the 10-mL volumetric 
flask and then diluted to volume with mobile phase. The 
mixture was sonicated for a minimum of 30 seconds with 
intermittent shaking. Then the solution was brought back 
to room temperature and diluted to the mark with mobile 
phase. Dilute 1mL of this solution to 5 mL with mobile 
phase. Place 1mL of the obtained solution in the 10-mL 
volumetric flask and make up to mark with mobile phase.
Measurements were made on the standard and test solu-
tions of spironolactone, standard and test solutions of po-
tassium orotate and mixture of these APIs. Three replicated 
injections of each standard preparation and mixture were 
injected and analyzed. The peaks were detected at 254 nm 
for spironolactone and at 278 nm for potassium orotate and 
identified using reference standards of spironolactone and 
potassium orotate.
Three replicated injections of each standard and test 
preparation and mixture were injected and analyzed accord-
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ing to the selected chromatographic conditions. The mean 
values of these three injections were used to evaluate reten-
tion time (tR), area of peak (A), theoretical plate (N), resolu-
tion factor (Rs) and concentrations for APIs.  The percent 
relative standard deviation (RSD, %), coefficient of variation 
(CV, %) values were used for evaluation of obtained values 
of spironolactone and potassium orotate separately and in 
the mixture. Concentrations of active substances in % were 
calculated according to the equation (1):
X% =                                            * 100% ,           (1)
Sx * mst * Wx*  P0
Sst * mx   *Wst
where, 
Sx – Average of area counts of principle peak obtained 
from the chromatograms of the test solution;
Sst -Average of area counts of principle peak obtained 
from the chromatograms of the standard solution;
mx – mass of test substance, g; 
mst – mass of standard substance, g; 
P₀ – Purity of reference standard (% w/w);
Wst and Wx – Dilution factor of standard and test solu-
tions, respectively. 
Results and discussion
There were analyzed several methods to develop a suit-
able and effective HPLC method for both the compatibility 
determination of potassium orotate in the combination with 
spironolactone and quantitative determination of them. 
Measurements were made on the pure substances, such 
as potassium orotate, spironolactone and mixture of them, 
using isocratic HPLC technique, carried out on the reversed 
phase chromatography and in the convenient chromato-
graphic conditions. By accurate analyses of the obtained 
chromatograms for solutions of potassium orotate (fig. 1 
and fig. 2), there were found the good shape of principal 
peak and its area, theoretical plate (N) and concentration, 
which are shown in table 1.
By accurate analyses of the obtained chromatograms for 
standard and test solutions of spironolactone (fig. 3), there 
were found the good shape of principal peak and its area, 
theoretical plate (N) and concentration, which are shown 
in table 2.
According to our preliminary data, it was found that the 
detection of potassium orotate is carried out at 278 nm with 
tR 3.06 min and spironolactone at 240 nm with tR 7.1min. 
Therefore, HPLC method for potassium orotate in combi-
nation with spironolactone was performed at different de-
tection wavelengths, which are specific for each active sub-
stance.
By accurate analyses of the values obtained from the 
chromatograms for the mixture it was found that potassium 
orotate and spironolactone eluted out forming symmetrical 
peaks, which were well separated from each other, applying 
mobile phase No 2. There was no additional peak in chro-
matograms (fig. 4).
By comparing the obtained chromatograms, it was 
shown that the separation  and simultaneous determina-
tion of two APIs on mobile phase N1 is difficult. Thus, it 
Table 1



























3.069 1.257 5976 2302 595.073 382.604 93.67 76.83
3.083 1.267 6084 2312 595.553 385.362 93.38 76.69
3.013 1.261 5709 2290 594.711 385.504 93.58 76.87
Mean. XX 3.06 1.26 5923 2301 595.11 384.49 93.55 76.79
RSD. % 0.04 0.005 192.85 11 0.422 1.635 0.15 0.09
CV. % 1.21 0.40 3.26 0.47 0.07 0.43 0.16 0.12
Fig. 1. Chromatograms of standard and test potassium orotate 
solutions at 278 nm on M/Ph no 1
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was concluded that the second mobile phase provided the 
good separation of potassium orotate and spironolactone. 
Fig. 4.  Chromatogram of mixture at 278 nm and 240nm 
simultaneously M/Ph. n1 and M/Ph no 2
Table 2










Spironolactone 7.019 16023 167.299 99.14
7.147 15263 175.151 99.26
7.148 16439 168.272 98.86
Mean. XX 7.10 15908 170.24 99.09
RSD. % 0.074 596 4.28 0.20
CV.% 1.04 3.75 2.51 0.20
Fig. 2. Chromatograms of standard and test potassium orotate 
solutions at 278 nm on M/Ph no 2
Fig. 3. Chromatograms of spironolactone standard and test 
solutions at 240 nm on M/Ph no 2
Furthermore, there were found the good shape of principal 
peaks and good resolution (Rs 36.04), which are shown in 
table 3.
The mixture of potassium orotate with spironolactone 
was evaluated in terms of concentration of each APIs from 
the mixture, according to the equation (1), relative standard 
deviation (RSD) and coefficient of variance (CV), which are 
shown in table 4 and table 5.
The chromatographic techniques developed and report-
ed in this study will serve as a basis for selecting the efficient 
method for separation and quantitative determination of 
both APIs simultaneously.
Therefore, it was determined that the concentration of 
spironolactone is 98.1% (RSD 0.21, CV 0.2%), obtained us-
ing mobile phase N2, and the concentration of potassium 
orotate is 91.68% (RSD 0.15, CV 0.16%), obtained using 
mobile phase N1. By undertaking of both chromatograms 
(fig.4) it was found that potassium orotate showed the good 
resolution from spironolactone on mobile phase, in which 
spironolactone is predominantly determined.
The method was found to be rapid as potassium orotate 
and spironolactone eluted out at 1.24 and 6.9 minutes re-
spectively, which is important for routine analysis.
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Conclusions
In the present study the compatibility between potassi-
um orotate and spironolactone in the mixture was carefully 
investigated by applying HPLC method.
Results demonstrated that there was no interaction be-
tween potassium orotate and spironolactone in the mixture, 
due to the absence of any additional peak in the chromato-
grams, which were investigated by HPLC method. Measure-
ments were performed on RP-18 reversed column (250*4 
mm, 5 μm), using mobile phase of acetonitrile: phosphate 
buffer solution with the ratio 50:50 (pH=4), at flow rate 
1.5 mL/min, injection volume 20 μL, temperature 40°C. By 
analyzing obtained HPLC chromatograms of the potassium 
orotate in the combination with spironolactone there were 
shown just 2 principal peaks at 1.24 min with the 278 nm 
detection wavelength, which is specific for potassium orotate 
and at 6.9 min with the 240 nm detection wavelength, which 
is specific for spironolactone.  Moreover, potassium orotate 
showed a good resolution from spironolactone: Rs 36.04. Po-
tassium orotate did not react with spironolactone, therefore 
the interaction wasn’t observed by HPLC. There was found 
the concentration of spironolactone (98.1% ±0.21), applying 
mobile phase N2, and the concentration of potassium oro-
tate (91.68% ± 0.15), applying mobile phase N1.
Thus, due to this method a conclusion was made that po-
tassium orotate is compatible with spironolactone. Further-
more, these results were confirmed by FT-IR spectroscopy.
References
1. Caplan MR, Daar ES, Corado KC. Next generation fixed-dose combina-
tion pharmacotherapies for treating HIV. Expert Opin Pharmacother. 
2018;19(6):589-596. doi:10.1080/14656566.2018.1450866.
2. Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Management of 
hypertension with a fixed-dose (single-pill) combination of bisoprolol 
and amlodipine. Clin Pharmacol Drug Dev. 2017;6(1):9-18. doi: 10.1002/
cpdd.309.
Table 3









Orotate K Spironolac. Orotate K Spironolac. Orotate K Spironolac. Orotate K Spironolac.
2259 17147 0.65 0.97 0.1046 0.2112 35.92
2266 17713 0.65 0.96 0.1044 0.2072 36.27
2272 17227 0.66 0.96 0.1044 0.2101 35.93
Mean. XX 2266 17362 0.65 0.96 0.10 0.21 36.04
RSD. % 6.16 306.05 0.004 0.005 0.0001 0.002 0.20
CV.% 0.27 1.76 0.62 0.49 0.11 0.99 0.56
Table 4











Mean. XX 3.06 1120.16 91.68
RSD. % 0.00 1.79 0.15
CV.% 0.03 0.16 0.16
Table 5







Orotate K Spironolac. Orotate K Spironolac. Orotate K Spironolac.
1.243 6.914 295.94 188.808 75.29 98.15
1.242 6.894 295.413 189.018 75.15 98.26
1.244 6.894 296.097 188.269 75.33 97.87
Mean. XX 1.24 6.90 295.82 188.70 75.26 98.10
RSD. % 0.001 0.01 0.36 0.39 0.09 0.20
CV.% 0.07 0.17 0.12 0.20 0.12 0.20
42
oriGiNal  researchE. Mazur et al. Moldovan Medical Journal. October 2020;63(4):35-42
3. Schlosser R. Fixed-dose and fixed-ratio combination therapies in 
type 2 diabetes.  Can J Diabetes. 2019;43(6):440-444. doi: 10.1016/j.
jcjd.2019.05.005.
4. Alfonzo AV, Isles C, Geddes C, et al. Potassium disorders – clinical 
spectrum and emergency management. Resuscitation. 2006;70(1):10-25. 
doi: 10.1016/j.resuscitation.2005.11.002.
5. Ashurst J, Sergent SR, Wagner BJ, Kim J. Evidence-based management 
of potassium disorders in the emergency department [digest]. Emerg 
Med Pract. 2016;18(11 Suppl Points & Pearls):S1-S2.
6. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, et al. The meaning of 
hypokalemia in heart failure. Int J Cardiol. 2012;158(1):12-17. doi: 
10.1016/j.ijcard.2011.06.121.
7. Elliott TL, Braun M. Electrolytes: potassium disorders. FP Essent. 2017 
Aug;459:21-28.
8. Udensi UK, Tchounwou PB. Potassium homeostasis, oxidative stress, and 
human disease. Int J Clin Exp Physiol. 2017;4(3):111-122. doi: 10.4103/
ijcep.ijcep_43_17.
9. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical 
characteristics in patients with coronavirus disease 2019 in Wenzhou, 
China. JAMA Netw Open. 2020;3(6):e2011122. doi: 10.1001/jamanet-
workopen.2020.11122. 
10. Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical 
update. Endocr Connect. 2018;7(4):R135-R146. doi: 10.1530/EC-18-
0109.
11. Lim S. Approach to hypokalemia. Acta Med Indones. 2007;39(1):56-64.
12. Wu KL, Cheng CJ, Sung CC, et al. Identification of the causes for chronic 
hypokalemia: importance of urinary sodium and chloride excretion. Am 
J Med. 2017;130(7):846-855. doi: 10.1016/j.amjmed.2017.01.023.
13. Dhondup T, Qian Q. Acid-base and electrolyte disorders in patients 
with and without chronic kidney disease: an update. Kidney Dis. 
2017;3(4):136-148. doi: 10.1159/000479968.
14. Lin SH, Halperin ML. Hypokalemia: a practical approach to diag-
nosis and its genetic basis. Curr Med Chem. 2007;14(14):1551-1565. 
doi:10.2174/092986707780831050.
15. Bielecka-Dabrowa A, Rysz J, Mikhailidis DP, et al. What is the risk 
of hyperkalaemia in heart failure? Expert Opin Pharmacother. 
2011;12(15):2329-2338. doi: 10.1517/14656566.2011.601743.
16. Weir MR, Espaillat R. Clinical perspectives on the rationale for po-
tassium supplementation. Postgrad Med. 2015;127(5):539-548. doi: 
10.1080/00325481.2015.1045814.
17. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-
aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-
548. doi: 10.2215/CJN.07821109.
18. Li H, Sun S, Chen J, et al. Genetics of magnesium disorders. Kidney Dis. 
2017;3(3):85-97. doi: 10.1159/000477730.
19. Mazur E. Noi tendințe de tratament a hipopotasiemiei cu medicamente 
combinate [New trends in the treatment of hypokalemia with combined 
drugs]. In: Conferinţa naţională de farmacie clinică „Farmacia clinică în 
secolul XXI” [National Conference of Clinical Pharmacy “Clinical phar-
macy in the XXI century”]. 3rd ed. 2019 Sep 19-21; Bucharest. Volume 
of abstracts]. Bucharest; 2019. p. 135-138. ISBN 978-973-0-24609-4. 
Romanian.
20. Uncu L, Donici E, Valica V, et al. Development and validation of an assay 
method for ciprofloxacin hydrochloride determination in combination 
ear drops. Chem J Mold. 2019;(2):56-61. doi: 10.19261/cjm.2019.607. 
21. Van Dooren AA. Design for drug-excipient interaction studies. Drug 
Dev Ind Pharm. 1983;9(1-2):43-55. doi: 10.3109/03639048309048544.
22. Jim LK. Physical and chemical compatibility of intravenous cipro-
floxacin with other drugs. Ann Pharmacother. 1993;27(6):704-707. doi: 
10.1177/106002809302700604.
23. Wyttenbach N, Birringer C, Alsenz J, et al. Drug-excipient compatibility 
testing using a high-throughput approach and statistical design. Pharm 
Dev Technol. 2005;10(4):499-505. doi: 10.1080/10837450500299875.
24. Roblek T, Vaupotic T, Mrhar A, et al. Drug-drug interaction soft-
ware in clinical practice: a systematic review. Eur J Clin Pharmacol. 
2015;71(2):131-142. doi: 10.1007/s00228-014-1786-7. 
25. Srikrishna S, Robinson D, Cardozo L. Important drug–drug interactions 
for treatments that target overactive bladder syndrome. Int Urogynecol 
J. 2014;25(6):715-720. doi: 10.1007/s00192-013-2259-8. 
26. Ryu JY, Kim HU, Lee SY. Deep learning improves prediction of 
drug-drug and drug-food interactions. Proc Natl Acad Sci USA. 
2018;115(18):E4304-E4311. doi: 10.1073/pnas.1803294115. 
27. Hartauer KJ, Guillory JK. A comparison of diffuse reflectance 
FT-IR spectroscopy and DSC in the characterization of a drug-
excipient interaction. Drug Dev Ind Pharm. 1991;17(4):617-630. doi: 
10.3109/03639049109044268.
28. Malan CE, de Villiers MM, Lotter AP. Application of differential scan-
ning calorimetry and high performance liquid chromatography to 
determine the effects of mixture composition and preparation during 
the evaluation of niclosamide-excipient compatibility. J Pharm Biomed 
Anal. 1997;15(4):549-57. doi: 10.1016/S0731-7085(96)01869-9.
29. Malan CE, de Villiers MM, Lotter AP. Evaluation of compatibility of tablet 
excipients with albendazole and closantel using DSC and HPLC. Drug 
Dev Ind Pharm. 1997;23(6):533-537. doi: 10.3109/03639049709149816.
30. Marrubini G, Tengattini S, Colombo R, et al. A new MS compatible 
HPLC-UV method for Teicoplanin drug substance and related impuri-
ties, part 1: Development and validation studies. J Pharm Biomed Anal. 
2019;162:185-191. doi: 10.1016/j.jpba.2018.09.040.
31. Mura P, Manderioli A, Bramanti G, et al. Utilization of differential 
scanning calorimetry as a screening technique to determine the compat-
ibility of ketoprofen with excipients. Int J Pharm. 1995;119(1):71-9. doi: 
10.1016/0378-5173(94)00374-E.
Authors’ ORCID iDs and academic degrees
Ecaterina Mazur, PharmD, PhD Applicant – https://orcid.org/0000-0003-0725-8410.
Martin Schmid, PharmD, Pharm PhD, Professor – https://orcid.org/0000-0003-0055-660X.
Livia Uncu, PharmD, Pharm PhD, Associate Professor – https://orcid.org/0000-0003-3453-2243.
Authors’ contribution: EM performed the technological and analytical parts of the laboratory work, interpreted the data, drafted the first 
manuscript. MS interpreted the data, revised the manuscript. LU designed the study, conducted the laboratory work, interpreted the data and 
revised the manuscript.  All the authors revised and approved the final version of the manuscript.
Funding: This study was supported by CEEPUS program mobility CIII-RO-0010-14-1920. The trial was the authors’ initiative. The authors are 
independent and take responsibility for the integrity of the data and accuracy of the data analysis.
Ethics approval and consent to participate: No approval was required for this study.
Conflict of Interests: No competing interests were disclosed.
Acknowledgment: We thank the coordinators of the CEEPUS program, especially the “Teaching and learning Bioanalysis” network, for the 
possibility of accessing mobility CIII-RO-0010-14-1920 and the opportunity to execute works within the Laboratory of Pharmaceutical Chem-
istry, Faculty of Pharmacy, University of Graz, Austria.
